Plasma β-amyloid in Alzheimer's disease and vascular disease
Open accessThe DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Abstract
Implementation of amyloid biomarkers in clinical practice would be accelerated if such biomarkers could be measured in blood. We analyzed plasma levels of Aβ42 and Aβ40 in a cohort of 719 individuals (the Swedish BioFINDER study), including patients with subjective cognitive decline (SCD), mild cognitive impairment (MCI), Alzheimer’s disease (AD) dementia and cognitively healthy elderly, using a ultrasensitive immunoassay (Simoa platform). There were weak positive correlations between plasma and cerebrospinal fluid (CSF) levels for both Aβ42 and Aβ40, and negative correlations between plasma Aβ42 and neocortical amyloid deposition (measured with PET). Plasma levels of Aβ42 and Aβ40 were reduced in AD dementia compared with all other diagnostic groups. However, during the preclinical or prodromal AD stages (i.e. in amyloid positive controls, SCD and MCI) plasma concentration of Aβ42 was just moderately decreased whereas Aβ40 levels were unchanged. Higher plasma (but not CSF) levels of Aβ were associated with white matter lesions, cerebral microbleeds, hypertension, diabetes and ischemic heart disease. In summary, plasma Aβ is overtly decreased during the dementia stage of AD indicating that prominent changes in Aβ metabolism occur later in the periphery compared to the brain. Further, increased levels of Aβ in plasma are associated with vascular disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 Correlations between plasma and CSF Aβ and between plasma Aβ and [18F]flutemetamol SUVR. (A–C) Plasma (Simoa immunoassay) and CSF (Euroimmun immunoassay) Aβ42 and Aβ40 were measured in a cohort of 719 individuals (174 SCI, 214 MCI, 57 AD patients and 274 controls). (D–F) Neuocortical amyloid deposition was measured using [18F]flutemetamol PET in a cohort of 340 individuals (103 SCI, 112 MCI patients and 125 controls). Correlation coefficients (r) and p-values are from Pearson’s correlation analysis. AD, Alzheimer’s disease; CSF, cerebrospinal fluid; SCD, subjective cognitive decline; MCI, mild cognitive impairment; PET, positron emission tomography; SUVR, standardized uptake value ratio.](https://figures.cochat.ai/paper-figures/71bfab0f50314c6182d3ebedc2d5d0c6/plasma-amyloid-in-alzheimer-s-disease-and-vascular-disease-figure-1.jpg)



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“more recent studies have demonstrated that it correlates with brain Aβ and can differentiate patients with AD from healthy control participants.12,13”
From Performance of Fully Automated Plasma Assays as Screening Tests for Alzheimer Disease–Related β-Amyloid Status (2019) · cites this paper as [13]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Many candidate blood biomarkers have failed in replication studies,7,8 but somewhat promising results have been seen for plasma tau, neurofilament light chain (NFL), and combinations of Aβ42 and Aβ40.9,10,11,12,13,14,15,16,17”
From Performance of Fully Automated Plasma Assays as Screening Tests for Alzheimer Disease–Related β-Amyloid Status (2019) · cites this paper as [13]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“a 65-year-old woman with only amyloid biomarkers but who is cognitively normal and has no neurodegeneration has a 10-year Alzheimer's disease risk of 2·5% and a man 2·3%, but the risk is higher with accompanying neurodegeneration (table 2 ).185”
From Dementia prevention, intervention, and care: 2020 report of the Lancet Commission (2020) · cites this paper as [185]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“A model of lifetime risks of people who are amyloid positive without any other biomarkers finds it to be 8·4% for a 90-year-old woman who is cognitively normal at baseline, 23·5% for a 75-year-old woman and 29·3% for a 65-year-old woman.185”
From Dementia prevention, intervention, and care: 2020 report of the Lancet Commission (2020) · cites this paper as [185]
Experimental — accuracy not yet measuredIn the citing paper
“Although previous studies have found associations between CSF and PET Aβ and plasma Aβ using different immunoassays,7,12,13,14,44,45 the present Elecsys assays produced among the best accuracies and they are the first fully automated assays to have these greater accuracies.”
From Performance of Fully Automated Plasma Assays as Screening Tests for Alzheimer Disease–Related β-Amyloid Status (2019) · cites this paper as [13]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657
Jack, C. R., Knopman, D. S., Jagust, W. J., Petersen, R. C., Weiner, M. W., Aisen, P. S., Shaw, L. M., Vemuri, P., Wiste, H. J., Weigand, S. D., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70291-0 · Cited by 4,396
Clinical and biomarker changes in dominantly inherited Alzheimer's disease
Bateman, R. J., Xiong, C., Benzinger, T. L. S., Fagan, A. M., Goate, A., Fox, N. C., Marcus, D. S., Cairns, N. J., Xie, X., Blazey, T. M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1202753 · Cited by 3,814
Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria
Dubois, B., Feldman, H. H., Jacova, C., Hampel, H., Molinuevo, J. L., Blennow, K., DeKosky, S. T., Gauthier, S., Selkoe, D., Bateman, R., et al. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70090-0 · Cited by 3,321
Self-citationRissin, D. M., Kan, C. W., Campbell, T. G., Howes, S. C., Fournier, D. R., Song, L., Piech, T., Patel, P. P., Chang, L., Rivnak, A. J., et al. (2010) · Nature Biotechnology · doi:10.1038/nbt.1641 · Cited by 2,119
Self-citationCerebrospinal fluid and plasma biomarkers in Alzheimer disease
Blennow, K., Hampel, H., Weiner, M., & Zetterberg, H. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.4 · Cited by 1,863
Self-citationA New Rating Scale for Age-Related White Matter Changes Applicable to MRI and CT
Wahlund, L. O., Barkhof, F., Fazekas, F., Bronge, L., Augustin, M., Sjögren, M., Wallin, A., Ader, H., Leys, D., Pantoni, L., et al. (2001) · Stroke · doi:10.1161/01.str.32.6.1318 · Cited by 1,797
Plasma phospholipids identify antecedent memory impairment in older adults
Mapstone, M., Cheema, A. K., Fiandaca, M. S., Zhong, X., Mhyre, T. R., MacArthur, L. H., Hall, W. J., Fisher, S. G., Peterson, D. R., Haley, J. M., et al. (2014) · Nature Medicine · doi:10.1038/nm.3466 · Cited by 1,043
Neurovascular mechanisms and blood–brain barrier disorder in Alzheimer’s disease
Bell, R. D., & Zlokovic, B. V. (2009) · Acta Neuropathologica · doi:10.1007/s00401-009-0522-3 · Cited by 860
Research works printed but not linked: 1
- Janelidze, S. et al. CSF Aβ42/Aβ40 and Aβ42/Aβ38 ratios: better diagnostic markers of Alzheimer disease. Annals of Clinical and Translational Neurology (In press).
Cited by
Items 301–400 of 628
Shin, Y. J., Evitts, K. M., Jin, S., Howard, C. C., Sharp-Milgrom, M., Schwarze‐Taufiq, T. A., Kinoshita, C., Young, J. E., & Zheng, Y. Y. (2023) · Neurobiology of Disease · doi:10.1016/j.nbd.2023.106125 · Cited by 26
Fang, X., Yang, Y., Wang, H., & Xu, H. Y. (2024) · Mechanobiology in Medicine · doi:10.1016/j.mbm.2024.100063 · Cited by 24
González‐Escalante, A., Milà‐Alomà, M., Brum, W. S., Ashton, N. J., Ortiz-Romero, P. L., Shekari, M., del Campo, M., Anastasi, F., Quijano‐Rubio, C., Kollmorgen, G., et al. (2025) · EBioMedicine · doi:10.1016/j.ebiom.2025.105741 · Cited by 33
Self-citationMehta, P. D., Patrick, B. A., Miller, D. L., Coyle, P. K., & Wısnıewskı, T. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-200861 · Cited by 24
Biomarkers and Tools for Predicting Alzheimer’s Disease in the Preclinical Stage
Li, T.-R., Yang, Q. Z., Hu, X., & Han, Y. (2021) · Current Neuropharmacology · doi:10.2174/1570159x19666210524153901 · Cited by 24
McCarter, S. J., Lesnick, T. G., Lowe, V. J., Rabinstein, A. A., Przybelski, S. A., Algeciras‐Schimnich, A., Ramanan, V. K., Jack, C. R., Petersen, R. C., Knopman, D. S., et al. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-220158 · Cited by 26
Mumtaz, I., Ayaz, M. O., Khan, M. S., Manzoor, U., Ganayee, M. A., Bhat, A. Q., Dar, G. H., Alghamdi, B. S. A., Hashem, A. M., Dar, M. J., et al. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.977411 · Cited by 24
Proteomic Indicators of Health Predict Alzheimer's Disease Biomarker Levels and Dementia Risk
Dark, H. E., Paterson, C., Daya, G. N., Peng, Z., Duggan, M. R., Bilgel, M., An, Y., Moghekar, A., Davatzikos, C. A., Resnick, S. M., et al. (2023) · Annals of Neurology · doi:10.1002/ana.26817 · Cited by 26
Maschio, V. P. D., Roveta, F., Bonino, L., Boschi, S., Rainero, I., & Rubino, E. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26178564 · Cited by 31
Bampatsias, D., Mavroeidis, I., Tual‐Chalot, S., Vlachogiannis, N. I., Bonini, F., Sachse, M., Mavraganis, G., Mareti, A., Kritsioti, C., Laina, A., et al. (2022) · Thrombosis and Haemostasis · doi:10.1055/a-1914-2094 · Cited by 23
Chang, Y., Chien, Y., Chang, C.-C., Wang, P., Chen, Y., & Chang, Y. C. (2024) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.3c12750 · Cited by 23
Research Progress on the Pathogenesis, Diagnosis, and Drug Therapy of Alzheimer’s Disease
Yang, Y., & Qiu, L. (2024) · Brain Sciences · doi:10.3390/brainsci14060590 · Cited by 23
Hideshima, S., Wustoni, S., Kobayashi, M., Hayashi, H., Kuroiwa, S., Nakanishi, T., & Ōsaka, T. (2018) · Sensing and Bio-Sensing Research · doi:10.1016/j.sbsr.2018.01.003 · Cited by 23
Brinkmalm, A., Portelius, E., Brinkmalm, G., Pannee, J., Dahlén, R., Gobom, J., Blennow, K., & Zetterberg, H. (2018) · Journal of Neurochemistry · doi:10.1111/jnc.14594 · Cited by 23
Self-citationPlasma Biomarkers: Potent Screeners of Alzheimer’s Disease
Naveed, M., Mubeen, S., Khan, A., Ibrahim, S., & Meer, B. (2019) · American Journal of Alzheimer s Disease & Other Dementias® · doi:10.1177/1533317519848239 · Cited by 27
Zhang, K., Yang, Q., Fan, Z., Zhao, J., & Li, H. (2019) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2019.111701 · Cited by 22
collaborators, F. T. I.-E., Vermunt, L., Terrera, G. M., ter Meulen, L., Veal, C., Blennow, K., Campbell, A., Carrié, I., Delrieu, J., Fauria, K., et al. (2020) · Alzheimer s Research & Therapy · doi:10.1186/s13195-019-0576-y · Cited by 21
Self-citationMcInerney, M. P., Short, J. L., & Nicolazzo, J. A. (2017) · The AAPS Journal · doi:10.1208/s12248-017-0077-5 · Cited by 22
Innovative Biomarkers for Alzheimer’s Disease: Focus on the Hidden Disease Biomarkers
Ghidoni, R., Squitti, R., Siotto, M., & Benussi, L. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-170953 · Cited by 22
Huang, Y., Li, Y., Xie, F., & Guo, Q. (2022) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.13962 · Cited by 22
Ni, M., Zhu, Z., Gao, F., Dai, L., Lv, X., Wang, Q., Zhu, X., Xie, J.-K., Shen, Y., Wang, S., et al. (2022) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.2c00636 · Cited by 21
de Souza, I. D., & Queiroz, M. E. C. (2023) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-023-04631-9 · Cited by 23
Profiling of plasma biomarkers in the context of memory assessment in a tertiary memory clinic
Bucci, M., Blūma, M., Savitcheva, I., Ashton, N. J., Chiotis, K., Matton, A., Kivipelto, M., Molfetta, G. D., Blennow, K., Zetterberg, H., et al. (2023) · Translational Psychiatry · doi:10.1038/s41398-023-02558-4 · Cited by 23
Self-citationIs blood pTau a reliable indicator of the CSF status? A narrative review
Antonioni, A., Raho, E. M., & Lorenzo, F. D. (2023) · Neurological Sciences · doi:10.1007/s10072-023-07258-x · Cited by 21
Colmant, L., Boyer, E., Gérard, T., Sleegers, K., Lhommel, R., Ivanoiu, A., Lefèvre, P., Kienlen‐Campard, P., & Hanseeuw, B. J. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25021173 · Cited by 23
Martínez‐Dubarbie, F., Guerra-Ruiz, A. R., López‐García, S., Lage, C., Fernández‐Matarrubia, M., Infante, J., Pozueta‐Cantudo, A., García‐Martínez, M., Corrales‐Pardo, A., Bravo, M., et al. (2024) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2024.152 · Cited by 20
Simino, J. M., Wang, Z., Bressler, J., Chouraki, V. A., Yang, Q., Younkin, S. G., Seshadri, S. S., Fornage, M., Boerwinkle, E., & Mosley, T. H. (2017) · PLoS ONE · doi:10.1371/journal.pone.0180046 · Cited by 22
Pang, S., & Cowen, S. (2017) · Scientific Reports · doi:10.1038/s41598-017-17823-y · Cited by 27
Tzekaki, E. E., Tsolaki, M., Pantazaki, Α. A., Geromichalos, G. D., Lazarou, E., Kozori, M., & Sinakos, Z. (2021) · Experimental Gerontology · doi:10.1016/j.exger.2021.111344 · Cited by 24
Pillet, L., Taccola, C., Cotoni, J., Thiriez, H., André, K., & Verpillot, R. (2020) · Translational Psychiatry · doi:10.1038/s41398-020-01102-y · Cited by 20
Digital Immunoassay for Proteins: Theory, Methodology, and Clinical Applications
Liu, X., Zhang, Q., Zong, C., & Gai, H. (2025) · Analytical Chemistry · doi:10.1021/acs.analchem.4c05421 · Cited by 24
Sung, W.-H., Hung, J., Lin, Y.-J., & Cheng, C. (2020) · Diagnostics · doi:10.3390/diagnostics10050272 · Cited by 19
Michno, W., Blennow, K., Zetterberg, H., & Brinkmalm, G. (2021) · Journal of Neurochemistry · doi:10.1111/jnc.15466 · Cited by 19
Self-citationAuNPs- Aβ-Ni-HRP sandwich assay: A new sensitive colorimetric method for the detection of Aβ 1-40
Khan, Z. A., & Park, S. (2021) · Talanta · doi:10.1016/j.talanta.2021.122946 · Cited by 21
Molecular Biomarkers of Neuronal Injury in Epilepsy Shared with Neurodegenerative Diseases
Negi, D., Granak, S., Shorter, S. A., O’Leary, V. B., Rektor, I., & Ovsepian, S. V. (2023) · Neurotherapeutics · doi:10.1007/s13311-023-01355-7 · Cited by 19
Tanaka, T., Chong, J. R., Nai, Y., Tan, C. H., Lim, C. Z. J., Zhang, Y., Stephenson, M. C., Hilal, S., Saridin, F. N., Gyanwali, B., et al. (2020) · European Journal of Neurology · doi:10.1111/ene.14704 · Cited by 20
Self-citationPlasma biomarkers are associated with agitation and regional brain atrophy in Alzheimer’s disease
Hsu, J.-L., Lee, W.-J., Liao, Y.-C., Lirng, J.-F., Wang, S.-J., & Fuh, J.-L. (2017) · Scientific Reports · doi:10.1038/s41598-017-05390-1 · Cited by 18
Imaging and Fluid Biomarkers of Alzheimer Disease: Complementation Rather Than Competition
Drzezga, A. E., & Barthel, H. (2025) · Journal of Nuclear Medicine · doi:10.2967/jnumed.125.270152 · Cited by 20
Jonesco, D. S., Karsdal, M. A., & Henriksen, K. (2020) · PLoS ONE · doi:10.1371/journal.pone.0234632 · Cited by 19
Wilczyńska, K., Maciejczyk, M., Zalewska, A., & Waszkiewicz, N. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.725511 · Cited by 20
Early Diagnosis of Alzheimer’s Disease: Moving Toward a Blood-Based Biomarkers Era
Tao, Q., Lin, R.-R., & Wu, Z. (2023) · Clinical Interventions in Aging · doi:10.2147/cia.s394821 · Cited by 23
Kesler, S. R., Henneghan, A. M., Prinsloo, S., Palesh, O. G., & Wintermark, M. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1199605 · Cited by 25
Ghazi, M. M., Selnes, P., Reina, S. T., Tecelão, S. R. R., Ingala, S., Bjørnerud, A., Kirsebom, B., Fladby, T., & Nielsen, M. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1345417 · Cited by 20
Pidal, J. M. G., Moreno‐Guzmán, M., Montero‐Calle, A., Barderas, R., López, M. Á., & Escarpa, A. (2024) · Sensors and Actuators B Chemical · doi:10.1016/j.snb.2024.136785 · Cited by 18
Biomarkers and Tools for Predicting Alzheimer's Disease in the Preclinical Stage
Li, T., Yang, Q. Z., Hu, X., & Han, Y. (2022) · Kölner Universitäts PublikationsServer (Universität zu Köln) · Cited by 17
Graff‐Radford, J., Mielke, M. M., Hofrenning, E. I., Kouri, N., Lesnick, T. G., Moloney, C. M., Rabinstein, A. A., Cabrera-Rodriguez, J. N., Rothberg, D. M., Przybelski, S. A., et al. (2022) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2022.07.006 · Cited by 18
Yu, F., Han, S., Salisbury, D. L., Pruzin, J. J., Geda, Y. E., Caselli, R. J., & Li, D. (2022) · Pilot and Feasibility Studies · doi:10.1186/s40814-022-01200-2 · Cited by 18
Predictive Utility of Plasma Amyloid and Tau for Cognitive Decline in Cognitively Normal Adults
Lee, Y.-J., Lin, S., Peng, S., Lin, Y., Chen, T.-B., Wang, P.-N., & Cheng, I. H. (2023) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2023.15 · Cited by 19
Gillespie, N. A., Elman, J. A., McKenzie, R. E., Tu, X. M., Xian, H., Reynolds, C. A., Panizzon, M. S., Lyons, M. J., Eglit, G. M. L., Neale, M. C., et al. (2023) · Alzheimer s & Dementia · doi:10.1002/alz.13407 · Cited by 14
Nielsen, J. E., Andreassen, T., Gotfredsen, C. H., Olsen, D. A., Vestergaard, K., Madsen, J. S., Kristensen, S. R., & Pedersen, S. (2024) · Metabolomics · doi:10.1007/s11306-023-02078-8 · Cited by 19
Amyloid-beta metabolism in age-related neurocardiovascular diseases
Aivalioti, E., Georgiopoulos, G. A., Tual‐Chalot, S., Bampatsias, D., Delialis, D., Sopova, K., Drakos, S. G., Stellos, K., & Stamatelopoulos, K. S. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae655 · Cited by 24
Alarcón‐Espósito, J., Mallea, M., & Rodríguez-Lavado, J. (2020) · Current Neuropharmacology · doi:10.2174/1570159x18666200914155951 · Cited by 26
Disease stage–specific atrophy markers in Alzheimer's disease
Baumeister, H., Gellersen, H. M., Polk, S. E., Lattmann, R., Wuestefeld, A., Wisse, L. E. M., Glenn, T. W., Yakupov, R., Stark, M., Kleineidam, L., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70482 · Cited by 23
Manjavong, M., Kang, J. M., Díaz, A. S., Ashford, M. T., Eichenbaum, J., Aaronson, A., Miller, M. J., Mackin, S., Tank, R., Weiner, M. W., et al. (2024) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2024.110 · Cited by 18
Ankeny, S. E., Bacci, J. R., Decourt, B., Sabbagh, M. N., & Mielke, M. M. (2024) · Neurology and Therapy · doi:10.1007/s40120-024-00658-x · Cited by 23
Mass spectrometric studies of the variety of beta‐amyloid proteoforms in Alzheimer's disease
Zakharova, N. V., Kononikhin, A. S., Indeykina, M. I., Bugrova, A. E., Strelnikova, P. A., Игоревич, П. С., Kozin, S. A., Popov, I. A., Mitkevich, V. A., Makarov, A. А., et al. (2022) · Mass Spectrometry Reviews · doi:10.1002/mas.21775 · Cited by 20
Blood-Based Kinase Assessments in Alzheimer’s Disease
Hugon, J., Mouton‐Liger, F., Cognat, E., Dumurgier, J., & Paquet, C. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00338 · Cited by 20
Lifestyle factors and plasma biomarkers of Alzheimer's disease: A narrative review
Hooper, C., Coley, N., Delrieu, J., & Guyonnet, S. (2025) · The Journal of Prevention of Alzheimer s Disease · doi:10.1016/j.tjpad.2025.100130 · Cited by 21
Non-Invasive Nasal Discharge Fluid and Other Body Fluid Biomarkers in Alzheimer’s Disease
Jung, D. H., Son, G., Kwon, O.-H., Chang, K., & Moon, C. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14081532 · Cited by 14
Brain perfusion, cognition, and plasma Alzheimer's biomarkers in moyamoya disease
Zou, X., Liao, Y., Jiang, C., Yuan, Y., Zhao, F., Ding, D., Liang, C., Xu, B., & Mao, Y. Q. (2023) · Alzheimer s & Dementia · doi:10.1002/alz.12958 · Cited by 16
Association of APOE ε4/ε4 with fluid biomarkers in patients from the PUMCH dementia cohort
Shang, L., Dong, L., Huang, X., Wang, T., Mao, C., Li, J., Wang, J., Liu, C., & Gao, J. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1119070 · Cited by 15
Twait, E. L., Min, B., Beran, M., Vonk, J. M. J., & Geerlings, M. I. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.101952 · Cited by 17
Navigating the Alzheimer’s Biomarker Landscape: A Comprehensive Analysis of Fluid-Based Diagnostics
Abiad, E. E., Al-Kuwari, A., Al-Aani, U., Jaidah, Y. A., & Châari, A. (2024) · Cells · doi:10.3390/cells13221901 · Cited by 21
Blood biomarkers for clinical applications in Alzheimer's disease: A narrative review
Li, H., & Wang, Z. (2025) · NeuroMarkers. · doi:10.1016/j.neumar.2025.100078 · Cited by 16
Retinol-Binding Protein Interferes with Transthyretin-Mediated β-Amyloid Aggregation Inhibition
Mangrolia, P., & Murphy, R. M. (2018) · Biochemistry · doi:10.1021/acs.biochem.8b00517 · Cited by 15
Vanderstichele, H., Teunissen, C. E., & Vanmechelen, E. (2019) · Neurology and Therapy · doi:10.1007/s40120-019-00166-3 · Cited by 15
Lee, J., Choi, Y. K., Chung, S., Yoon, D. H., Choi, S. H., Kang, S. M., Seo, D., & Park, K. (2020) · Diagnostics · doi:10.3390/diagnostics10040237 · Cited by 15
Madrid, L., Castro‐Labrador, S., González‐Pérez, A., Sáez, M. E., & (ADNI), T. A. D. N. I. (2021) · Diagnostics · doi:10.3390/diagnostics11122303 · Cited by 16
Effect of DPP-4 inhibitor on elderly patients with T2DM combined with MCI
Xue, J., Wang, C., Pan, C., Xing, H., Xu, L., Chen, X., Wang, X., & Wang, N. (2019) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2019.8339 · Cited by 18
Arranz, J., Zhu, N., Rubio‐Guerra, S., Rodríguez‐Baz, Í., Ferrer, R., Carmona‐Iragui, M., Barroeta, I., Illán‐Gala, I., Santos‐Santos, M., Fortea, J., et al. (2023) · Research Square · doi:10.21203/rs.3.rs-3725688/v1 · Cited by 15
Khowdiary, M. M., Al-Kuraishy, H. M., Al-Gareeb, A. I., Albuhadily, A. K., Elhenawy, A. A., Rashwan, E. K., Alexiou, A. T., Papadakis, M., Fetoh, M. E. A., & Batiha, G. E. (2025) · NeuroMolecular Medicine · doi:10.1007/s12017-025-08836-2 · Cited by 15
FTIR Spectroscopy and Blood-Derived Extracellular Vesicles Duo in Alzheimer’s Disease
Martins, T. S., Ferreira, M., Magalhães, S., Leandro, K., de Almeida, L. P., Vogelgsang, J. S., Breitling, B., Hansen, N., Esselmann, H., Wiltfang, J., et al. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-231239 · Cited by 20
Blömeke, L., Rehn, F., Pils, M., Kraemer‐Schulien, V., Cousin, A., Kutzsche, J., Bujnicki, T., Freiesleben, S. D., Schneider, L., Preis, L., et al. (2024) · Communications Medicine · doi:10.1038/s43856-024-00690-w · Cited by 15
Circulating APP, NCAM and Aβ serve as biomarkers for Alzheimer’s disease
Chen, K., Gao, T., Bai, Z., & Yuan, Z. (2018) · Brain Research · doi:10.1016/j.brainres.2018.08.015 · Cited by 14
Lin, F. V., Heffner, K. L., Gevirtz, R., Zhang, Z., Tadin, D., & Porsteinsson, A. P. (2021) · Trials · doi:10.1186/s13063-021-05530-z · Cited by 18
Periphery Biomarkers for Objective Diagnosis of Cognitive Decline in Type 2 Diabetes Patients
Liu, Y., Zhang, S., He, B., Chen, L., Ke, D., Zhao, S., Zhang, Y., Wei, W., Xu, Z., Xu, Z., et al. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.752753 · Cited by 17
Saif, N., Hristov, H., Akiyoshi, K., Niotis, K., Ariza, I. E., Malviya, N., Lee, P., Melendez, J., Sadek, G., Hackett, K., et al. (2022) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2022.44 · Cited by 13
Relationship of amyloid-β1–42 in blood and brain amyloid: Ginkgo Evaluation of Memory Study
López, O. L., Klunk, W. E., Mathis, C. A., Snitz, B. E., Chang, Y., Tracy, R. P., & Kuller, L. H. (2019) · Brain Communications · doi:10.1093/braincomms/fcz038 · Cited by 15
Larsen, J. R., Kobborg, T., Shahim, P., Blennow, K., Rasmussen, L. S., & Zetterberg, H. (2020) · Acta Anaesthesiologica Scandinavica · doi:10.1111/aas.13691 · Cited by 13
Self-citationde Kort, A. M., Kuiperij, H. B., Jäkel, L., Kersten, I., Rasing, I., van Etten, E. S., van Rooden, S., van Osch, M. J. P., Wermer, M. J. H., Terwindt, G. M., et al. (2023) · Alzheimer s Research & Therapy · doi:10.1186/s13195-023-01245-2 · Cited by 14
Giuffrè, G. M., Quaranta, D., Vita, M. G., Costantini, E. M., Citro, S., Carrozza, C., Ninno, G. D., Calabresi, P., & Marra, C. (2024) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2024.58 · Cited by 14
Spatial extent as a sensitive amyloid‐PET metric in preclinical Alzheimer's disease
Farrell, M. E., Thibault, E. G., Becker, J. A., Price, J. C., Healy, B. C., Hanseeuw, B. J., Buckley, R. F., Jacobs, H. I. L., Schultz, A. P., Chen, C. D., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14036 · Cited by 16
How to measure and model cardiovascular aging
Spray, L., Richardson, G. D., Booth, L. K., Haendeler, J., Altschmied, J., Bromage, D. I., Wallis, S. B., Stellos, K., Tual‐Chalot, S., & Spyridopoulos, I. (2025) · Cardiovascular Research · doi:10.1093/cvr/cvaf138 · Cited by 14
Piscitelli, F., Coccurello, R., Totaro, A., Leuti, A., Giacovazzo, G., Verde, R., Rossi, E., Vulpiani, M. P., Ferri, N., Stuffler, R. G., et al. (2019) · European Journal of Lipid Science and Technology · doi:10.1002/ejlt.201900015 · Cited by 13
Alzheimer's disease diagnosis by blood plasma molecular fluorescence spectroscopy (EEM)
Santos, R. F., Paraskevaidi, M., Mann, D. M. A., Allsop, D., Santos, M. C. D., Morais, C. L. M., & Lima, K. M. G. (2022) · Scientific Reports · doi:10.1038/s41598-022-20611-y · Cited by 16
Sapkota, S., Erickson, K., Fletcher, E. M., Farias, S. T., Jin, L., DeCarli, C. S., & Initiative, A. D. N. (2023) · Stroke · doi:10.1161/strokeaha.122.041854 · Cited by 13
Enlarged perivascular spaces and plasma Aβ42/Aβ40 ratio in older adults without dementia
Kapoor, A., Gaubert, A., Yew, B., Jang, J. Y., Dutt, S., Li, Y., Alitin, J. P. M., Nguyen, A., Ho, J. K., Blanken, A. E., et al. (2023) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2023.04.004 · Cited by 13
Xu, Y., Jiang, H., Zhu, B., Cao, M., Feng, T., Sun, Z., Du, G., & Zhao, Z. (2023) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.14238 · Cited by 11
Green, Z. D., Kueck, P. J., John, C. S., Burns, J. M., & Morris, J. K. (2023) · Current Alzheimer Research · doi:10.2174/0115672050271523231111192725 · Cited by 11
Zhou, A. L., Swaminathan, S. K., Salian, V. S., Wang, L., Curran, G. L., Min, H.-K. P., Lowe, V. J., & Kandimalla, K. K. (2024) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.3c00784 · Cited by 14
Glymphatic Impairment Associated with Neurocognitive Dysfunction in Moyamoya Disease
Zeng, C., Zhai, Y., Ge, P., Liu, C., Yu, X., Liu, W., Li, J., He, Q., Liu, X., Ye, X., et al. (2024) · Translational Stroke Research · doi:10.1007/s12975-024-01250-z · Cited by 16
Kanuri, S. H., & Sirrkay, P. J. (2024) · Brain Circulation · doi:10.4103/bc.bc_113_23 · Cited by 13
Amyloid Metabolism and Amyloid-Targeting Blood-Based Biomarkers of Alzheimer’s Disease
Pyun, J., Kang, M. J., Ryoo, N., Suh, J., Youn, Y. C., Park, Y. H., & Kim, S. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-200104 · Cited by 12
Saunders, T. S., Gadd, D. A., Spires‐Jones, T. L., King, D., Ritchie, C. W., & Terrera, G. M. (2022) · European Journal of Neuroscience · doi:10.1111/ejn.15656 · Cited by 13
Wolters, F. J., Hilal, S., Leening, M. J. G., Kavousi, M., Ghanbari, M., Franco, O. H., Hofman, A., Koudstaal, P. J., Vernooij, M. W., Ikram, M. K., et al. (2022) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2022.03.025 · Cited by 13
Hajjar, I. M., Neal, R. M., Yang, Z., & Lah, J. J. (2024) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12581 · Cited by 11
Zhang, Z., Sheng, Z.-H., Liu, J. Y., Zhang, D., Wang, H., Wang, L., Zhu, Y., Ma, L., & Tan, L. (2024) · Journal of Alzheimer s Disease · doi:10.1177/13872877241284216 · Cited by 11
Tian, Q., Greig, E. E., Walker, K. A., Duggan, M. R., Yang, Z., Moghekar, A., Landman, B. A., Davatzikos, C. A., Resnick, S. M., & Ferrucci, L. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.14612 · Cited by 13
Chen, Y., Zeng, X., Olvera‐Rojas, M., Sewell, K. R., Sehrawat, A., Gu, J. M., Triviño‐Ibáñez, E. M., Solis‐Urra, P., Gómez-Río, M., Oberlin, L. E., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-68372-w · Cited by 13
Huang, Y., Zheng, H., Tan, K., Sun, X., Ye, J., & Zhang, Y. (2020) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756286420947973 · Cited by 12
Metadata
- Authors
- Janelidze, S., Stomrud, E., Palmqvist, S., Zetterberg, H., van Westen, D., Jeromin, A., Song, L., Hanlon, D., Tan Hehir, C. A., Baker, D., Blennow, K., & Hansson, O.
- Affiliations
- Lund University (SE)
- National Hospital for Neurology and Neurosurgery (GB)
- Quanterix (United States) (US)
- University of Gothenburg (SE)
- Corresponding author
- Janelidze, Shorena
- Hansson, Oskar
- ORCID
- Venue
- Scientific Reports
- Published
- 2016-05-31
- Volume
- 6
- Issue
- 1
- Pages
- 26801-26801
- ISSN
- 2045-2322 (ISSN-L)
- PMC
- PMC4886210
- OpenAlex
- W2414917913
- Cited by
- 626
- References
- 49
- Citations by year
- 2026: 53 · 2025: 59 · 2024: 75 · 2023: 77 · 2022: 80 · 2021: 75 · 2020: 73 · 2019: 59 · 2018: 45 · 2017: 22 · 2016: 6
- FWCI
- 39.10
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Scientific Reports (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Lund University Publications (Lund University) (submittedVersion)
- Funders
- Australian Government
- Crafoordska Stiftelsen
- Lunds Universitet
- Vetenskapsrådet
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- plasma amyloid-beta, amyloid-beta 42, Aβ40, Alzheimer's disease, vascular disease, amyloid biomarkers, cerebrospinal fluid, white matter lesions, cerebral microbleeds, hypertension, diabetes mellitus, ischemic heart disease, mild cognitive impairment, subjective cognitive decline, amyloid PET, amyloid metabolism
- MeSH terms
- Aged, Alzheimer Disease, Female, Humans, Male, Vascular Diseases, Cohort Studies, Biomarkers, Amyloid beta-Peptides, Neocortex, Positron-Emission Tomography, Apolipoprotein E4
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.